Etid klinik pou Lupus nan Kalifòni
27 etid pou Lupus ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
- Santa Monica8 etid
- Los Angeles8 etid
- Buena Park7 etid
- San Diego7 etid
- Fullerton5 etid
- San Francisco4 etid
- Upland3 etid
- Sacramento3 etid
- San Leandro3 etid
Tèks ofisyèl etid la (Anglè)
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Providence Medical Center, Burbank
- Advanced Medical Research, La Palma
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT06133972Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Ronald Reagan UCLA Medical Center, Los Angeles
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT05268289A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Wallace & Lee Center, Beverly Hills
- Arthritis & Osteoporosis Medical Center, Inc - La Palma, La Palma
- University of California San Diego, San Diego
- ak 3 plis
Ap rekriteFaz 2
Laj 18 a 74 · Tout sèks · Mizajou Oct 1, 2026 · NCT07409181An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Los Angeles
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 30, 2026 · NCT05835310A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Fontana
- Research Site, La Jolla
- Research Site, La Palma
- ak 3 plis
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- David S Hallegua MD A Professional Corporation, Beverly Hills
- Providence Medical Foundation, Fullerton
- Southland Arthritis and Osteoporosis Medical Center Inc dba Southland Arthritis, Hemet
- ak 5 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Solace Research /ID# 279155, Tustin
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07607964Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Research Site, Fullerton
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Sep 18, 2026 · NCT07201558A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Research Site, La Jolla
- Research Site, Sacramento
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 15, 2026 · NCT06916806A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Inland Rheumatology Clinical Trials, Inc., Upland
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT07355218Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
- University of California San Francisco - Zuckerberg San Francisco General, San Francisco
Ap rekriteFaz 1
Laj 18 a 60 · Tout sèks · Mizajou Sep 14, 2026 · NCT06975787A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
- Wallace Rheumatic Studies Center, Beverly Hills
- Kaiser Permanente Fontana, Fontana
- Providence Medical Foundation, Fullerton
- ak 2 plis
Ap rekriteFaz 2
Laj 12 a 70 · Tout sèks · Mizajou Sep 14, 2026 · NCT07570862A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Dermatology Research Associates - 300204025, Los Angeles
- Cohen Medical Centers, Thousand Oaks
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 11, 2026 · NCT07332481A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, San Francisco
- Research Site, Stanford
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 10, 2026 · NCT06897930A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50737, Beverly Hills
- Sl0044 50775, Beverly Hills
- Sl0044 50257, La Jolla
- ak 6 plis
Ap rekriteFaz 3
Laj 16 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06617325A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Local Institution - 0054, La Jolla
- Local Institution - 0001, La Palma
- Local Institution - 0071, Los Angeles
- ak 1 plis
Ap rekriteEtid obsèvasyon
Laj 16 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07175285FT839 in Autoimmune Diseases
- Providence Medical Foundation, Fullerton
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 2, 2026 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of California Irvine, Orange
- UC Davis Health, Sacramento
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
- University of California, Los Angeles, Los Angeles
- University of California: San Diego, San Diego
Ap rekriteFaz 3
Laj 55 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05799378A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
- Investigative Site, Beverly Hills
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Jul 27, 2026 · NCT07260877Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
- Carewell Arthritis Center, Apple Valley
- Attune Health Research Inc, Beverly Hills
- Covina Arthritis Clinic, Covina
- ak 4 plis
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Jul 20, 2026 · NCT07237659A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
- US06-0, La Palma
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Jun 2, 2026 · NCT06625671A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- ak 2 plis
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Lupus Landmark Study: A Prospective Registry and Biorepository
- Wallace Rheumatic Studies Center, Beverly Hills
- UCLA, Los Angeles
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Apr 15, 2026 · NCT05934149Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.